Montara Therapeutics Reimagines Blood-Brain Barrier as Solution, Not Problem, Secures $1M for Brain-Selective mTOR Therapy

August 9, 2026

Drug Discovery News USA

Overview

Montara Therapeutics is pioneering an approach to blood-brain barrier (BBB) drug delivery by leveraging the BBB to its advantage for brain-selective pharmacology. Instead of forcing drugs across, their technology restricts drug activity outside the brain, enabling higher brain concentrations while minimizing peripheral toxicities. This innovative strategy recently secured $1 million in funding from The Michael J. Fox Foundation for a brain-selective mTOR therapy for Parkinson’s disease, challenging conventional BBB permeation methods.

In Depth

Key Findings

Montara Therapeutics is spearheading a groundbreaking shift in the paradigm of blood-brain barrier (BBB) drug delivery, proposing that the BBB can be leveraged as a ‘solution’ rather than solely a ‘problem.’ Their innovative technology aims to achieve brain-selective pharmacology by actively restricting drug activity outside the brain, thereby enabling higher therapeutic concentrations within the brain while minimizing systemic toxicities. This novel strategy recently garnered a $1 million funding commitment from The Michael J. Fox Foundation to advance a brain-selective mTOR therapy for Parkinson’s disease, representing a significant departure from conventional BBB-bypassing approaches.

Technical / Clinical Details

Montara Therapeutics’ approach involves designing therapeutic molecules that either become inactive outside the brain after crossing the BBB or are inherently restricted from peripheral activity through a prodrug strategy. This allows for maximal therapeutic exposure in the brain while significantly reducing systemic drug load and associated side effects. For instance, mTOR, a critical cellular pathway implicated in Parkinson’s disease, is ubiquitously expressed throughout the body, and systemic mTOR inhibition can lead to severe adverse events. Montara’s brain-selective mTOR therapy aims to modulate this pathway specifically within the central nervous system, utilizing the BBB’s inherent selectivity to its advantage. This method contrasts sharply with techniques like focused ultrasound or chemical modifications that aim to ‘open’ or ‘permeabilize’ the BBB, which can carry risks of inflammation or non-specific drug entry. By re-envisioning the BBB from a protective barrier to a selective delivery system, Montara seeks to achieve a superior therapeutic index for brain disorders.

Background & Context

The blood-brain barrier is a formidable biological impediment that blocks over 98% of small-molecule drugs and nearly all large-molecule therapeutics from entering the brain. This has historically been the primary challenge in developing effective treatments for devastating neurological disorders such as brain tumors, Alzheimer’s disease, and Parkinson’s disease. While extensive research has focused on strategies to enhance BBB penetration (e.g., direct injection, osmotic disruption, transporter-mediated delivery), these often involve invasive procedures or risks of non-specific brain exposure and peripheral side effects. Montara Therapeutics’ strategy represents a conceptual reversal, seeking to exploit the BBB’s protective properties for therapeutic benefit rather than merely overcoming them. This reinterpretation aligns with a growing understanding of the complex biology of the BBB and its potential as a selective gatekeeper for brain pharmacology.

Strategic Significance & Outlook

Montara Therapeutics’ ‘BBB as a solution’ approach could open entirely new frontiers in the development of therapies for central nervous system disorders. The $1 million funding from The Michael J. Fox Foundation is a crucial validation and accelerates the development of their Parkinson’s disease mTOR therapy. If successful in preclinical and clinical trials, this technology has the potential to set a new standard for brain-selective drug delivery. Its applicability extends across a broad spectrum of brain conditions, including neurodegenerative diseases, psychiatric disorders, and brain cancers, where minimizing peripheral toxicity is paramount. The pharmaceutical industry will keenly watch its progress, as this approach could unlock previously intractable targets and lead to safer, more effective treatments for patients worldwide, fundamentally changing how we approach brain drug development.

Source: https://www.drugdiscoverynews.com/what-if-the-blood-brain-barrier-is-the-solution-not-the-problem-17407

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.